Interview: Justin Hanka: Co-founder and Executive Director: MindBio Therapeutics
About the Author: HCN News Team
The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.
Related Posts
Latest News
Tilray Brands Reports Q2 Fiscal 2026 Financial Results
NEW YORK – Tilray Brands Inc. posted net revenue of $217.5 million for its fiscal second quarter ended November 30, 2025, marking the company's highest quarterly figure to date and edging up 3% from $211 ...
Helus Pharma Rings Nasdaq Bell Post-Cybin Rebrand
TORONTO – Helus Pharma Inc., rebranded from Cybin Inc., opened trading on the Nasdaq Global Market under the ticker symbol $HELP, marking a shift from the NYSE American where it previously traded as $CYBN. The ...
Who Will Decide Cannabis Legalization? The Math Will.
LOS ANGELES -For decades, Cannabis reform in the United States has moved unevenly—state by state, ballot by ballot, crisis by crisis. On paper, federal prohibition still stands, and national politics remain polarized. But economically and ...
